Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) saw a large decline in short interest in July. As of July 15th, there was short interest totalling 3,880,000 shares, a decline of 19.2% from the June 30th total of 4,800,000 shares. Based on an average daily volume of 869,400 shares, the days-to-cover ratio is presently 4.5 days.
Analyst Upgrades and Downgrades
WVE has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Wave Life Sciences in a research note on Wednesday, June 26th. Truist Financial restated a “buy” rating and set a $17.00 target price on shares of Wave Life Sciences in a research report on Monday, April 1st. Mizuho reiterated an “outperform” rating and issued a $19.00 price target on shares of Wave Life Sciences in a report on Tuesday, June 25th. Wells Fargo & Company assumed coverage on shares of Wave Life Sciences in a report on Wednesday, May 15th. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, StockNews.com cut shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $13.17.
Check Out Our Latest Stock Analysis on Wave Life Sciences
Institutional Trading of Wave Life Sciences
Wave Life Sciences Trading Down 0.3 %
NASDAQ:WVE opened at $6.51 on Tuesday. Wave Life Sciences has a twelve month low of $3.50 and a twelve month high of $7.67. The company has a market capitalization of $797.28 million, a P/E ratio of -12.52 and a beta of -1.12. The firm has a 50-day moving average price of $5.83 and a two-hundred day moving average price of $5.44.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $12.54 million during the quarter, compared to analysts’ expectations of $25.67 million. During the same period in the prior year, the company earned ($0.27) EPS. On average, equities research analysts predict that Wave Life Sciences will post -0.85 earnings per share for the current year.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Recommended Stories
- Five stocks we like better than Wave Life Sciences
- The 3 Best Blue-Chip Stocks to Buy Now
- Survey: Top 175 Fittest Retirement Locations in America
- Following Congress Stock Trades
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Bank Stocks – Best Bank Stocks to Invest In
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.